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Abstract
The mortality associated with invasive fungal infections remains high with that involving rare yeast pathogens other than Candida being no
exception. This is in part due to the severe underlying conditions typically predisposing patients to these healthcare-related infections (most
often severe neutropenia in patients with haematological malignancies), and in part due to the often challenging intrinsic susceptibility pattern of
the pathogens that potentially leads to delayed appropriate antifungal treatment. A panel of experts of the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and the European Confederation of Medical Mycology
(ECMM) undertook a data review and compiled guidelines for the diagnostic tests and procedures for detection and management of rare
invasive yeast infections. The rare yeast pathogenswere deﬁned and limited to the following genera/species: Cryptococcus adeliensis,Cryptococcus
albidus, Cryptococcus curvatus, Cryptococcus ﬂavescens, Cryptococcus laurentii and Cryptococcus uniguttulatus (often published under the name
Filobasidium uniguttulatum),Malassezia furfur,Malassezia globosa,Malassezia pachydermatis andMalassezia restricta, Pseudozyma spp., Rhodotorula
glutinis, Rhodotorula minuta and Rhodotorula mucilaginosa, Sporobolomyces spp., Trichosporon asahii, Trichosporon asteroides, Trichosporon dermatis,
Trichosporon inkin, Trichosporon jirovecii, Trichosporon loubieri, Trichosporon mucoides and Trichosporon mycotoxinivorans and ascomycetous ones:
Geotrichum candidum, Kodamaea ohmeri, Saccharomyces cerevisiae (incl. S. boulardii) and Saprochaete capitatae (Magnusiomyces (Blastoschizomyces)
capitatus formerly named Trichosporon capitatum or Geotrichum (Dipodascus) capitatum) and Saprochaete clavata. Recommendations about the
microbiological investigation and detection of invasive infection were made and current knowledge on the most appropriate antifungal and
supportive treatment was reviewed. In addition, remarks about antifungal susceptibility testing were made.
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Introduction
In 2012 the ﬁrst ofﬁcial European Society for Clinical
Microbiology and Infectious Diseases (ESCMID) guideline on
the diagnosis and treatment of a fungal infection was published
[1–6]. Mucosal and invasive candidosis were covered and a
comprehensive consensus guideline was developed with the
participation of many experts from the ESCMID Fungal
Infection Study Group (EFISG) representing many European
countries. Before publication the recommendations were
presented for discussion at a European Congress for Clinical
Microbiology and Infectious Diseases (ECCMID) workshop
and the subsequent manuscripts underwent peer-review
before publication in the ESCMID journal, Clinical Microbiology
and Infection.
Following the same rigorous procedure, EFISG continued
the ESCMID guideline development process—this time in
collaboration with the European Confederation of Medical
Mycology (ECMM) and focusing on rare invasive fungal
infections. The deﬁnition of such pathogens is somewhat
pragmatic but yeasts other than Candida, mucorales, hyalo-
hyphomycetous and dematiaceous fungi that are not common
causes of invasive infections were included. This guideline
presents the diagnostic and management guideline for ‘rare
invasive yeast infections’ including several basidiomycetous
yeasts: Cryptococcus adeliensis, Cryptococcus albidus, Cryptococcus
curvatus, Cryptococcus ﬂavescens, Cryptococcus laurentii and
Cryptococcus uniguttulatus (often published under the name
Filobasidium uniguttulatum), Malassezia furfur, Malassezia globosa,
Malassezia pachydermatis and Malassezia restricta, Pseudozyma
spp., Rhodotorula glutinis, Rhodotorula minuta and Rhodotorula
mucilaginosa, Sporobolomyces spp., Trichosporon asahii, Trichospo-
ron asteroides, Trichosporon dermatis, Trichosporon inkin, Tricho-
sporon jirovecii, Trichosporon loubieri, Trichosporon mucoides and
Trichosporon mycotoxinivorans and ascomycetous ones: Geotri-
chum candidum, Kodamaea ohmeri, Saccharomyces cerevisiae
(incl. S. boulardii) and Saprochaete capitatae (Magnusiomyces
(Blastoschizomyces) capitatus formerly named Trichosporon ca-
pitatum or Geotrichum (Dipodascus) capitatum) and Saprochaete
clavata.
The selection of organisms has been based on the following
criteria: (i) species were only included if they were docu-
mented as a cause of human invasive infections and (ii) rare
Candida species were excluded because we anticipate that
readers would probably refer to the ESCMID Candida
guidelines rather than a rare invasive yeast infection guideline
concerning species like Candida palmioleophila etc. although
such species fulﬁl the term of being a rare cause of invasive
infections. The species not considered being documented as
cause of invasive human disease included Cryptococcus albido-
similis, Cryptococcus difﬂuens, Cryptococcus humicola and Crypto-
coccus uzbekistanensis, Trichosporon spp. others than those
mentioned above, Blastobotrys proliferans, Millerozyma farinosa,
Ogataea polymorpha and Guehomyces pullulans. Finally, the
guideline was limited to true yeasts and hence the unicellular
algae Prototheca wickerhamii and Prototheca zopﬁi var. zopﬁi
were excluded although we realize they have been misiden-
tiﬁed as yeasts on occasion.
For the uncommon Candida species we refer the reader to
the general recommendations regarding diagnosis and treat-
ment as described in the ESCMID Candida guideline [1–6].
However, as some of these species are characterized by
unique intrinsic susceptibility patterns, which are not specif-
ically addressed in the Candida guidelines, a table summarizing
this information has been elaborated and included here
(Table 1, [7–19]). This table also includes names used in the
anamorphic and teleomorphic states, despite this distinction
recently being made superﬂuous [20].
General recommendations regarding collection, transport
and storage of clinical specimens, direct examination, isolation
and identiﬁcation procedures, which are valid for all
yeast-associated human infections, can be found in appropriate
textbooks (e.g. Barnett et al. [21]) and are not mentioned
here. Only speciﬁc features regarding genus identiﬁcations for
the speciﬁc yeasts discussed herein were considered. The
methods to evaluate the quality of evidence and to reach
consensus recommendations were described previously [1].
Strength of recommendations’ quality of evidence was graded
according to the criteria outlined in Table 2.
Rare Invasive Yeast Infections
It is important to underscore that the fungal organisms
covered in this guideline are not rare per se. A number of the
‘rare yeasts’ are encountered as frequent colonizers of human
skin, mucosal surfaces, in food items or in the environment. In
the normal host, infections are typically limited to various
superﬁcial infections like pityriasis versicolor, white piedra and
occasionally onychomycosis, the management of which are
dealt with in dermatology guidelines [22–25]. However, in the
immunosuppressed or otherwise compromised host, invasive
infections may occur, some being related to the presence of a
central venous catheter (CVC) and a few reported as
nosocomial clusters that require molecular approaches to be
properly documented. As predicted from their low pathoge-
nicity, invasive infections are still reported at low numbers in
severely immunocompromised hosts (Table 3) [26–30]. For
example, these organisms together constituted 1.1% of the
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almost 4000 fungaemia isolates in an 8-year national surveil-
lance programme in Denmark [26,27]. In Paris, they repre-
sented 5.1% of the 3668 fungaemia isolates in a prospective
surveillance programme from 2002 to 2012 (YEASTS Network,
National Reference Centre for Invasive Mycoses and Antifun-
gals, Paris, France (O. Lortholary, unpublished data), Table 3).
Saccharomyces cerevisiae is a biotechnologically highly important
fungus with a broad use in the production of food and alcoholic
beverages etc. Phylogenetically, the species is relatively closely
related to Candida glabrata [31].
As most of these rare invasive yeast infections occur in the
haematology and Intensive Care Unit (ICU) settings, clinicians
should be aware that all of the responsible fungal species,
presumably except Saccharomyces spp. and Kodamaea ohmeri,
are regarded as intrinsically resistant to echinocandins. As a
result of the rare nature of these pathogens, controlled
prospective and comparative clinical trials are not feasible so
solid data on treatment efﬁcacy cannot be compiled. More-
over, clinical susceptibility breakpoints have not been estab-
lished. Hence, management recommendations derive from
clinical experience (cohort or case–controlled analytical stud-
ies, from multiple time series), pragmatic interpretations of
susceptibility data and limited animal studies when available.
Also because of their rare incidence, primary prophylaxis is
not indicated unless speciﬁc local epidemiology suggests
otherwise. As speciﬁc diagnostic surrogate markers have not
been developed for these organisms (apart from the antigen
test for Cryptococcus but mainly evaluated for Cryptococcus
TABLE 1. Summary of rare Candida species that have been associated with human infection (by anamorphic and teleomorphic
name). Remarks that may be relevant in the clinical context are included. References are kept to a minimum as these species are
not the topic of this guideline
Anamorphic state Teleomorphic state Speciﬁc comment relevant in clinical context
C. africana Not described Closely related to C. albicans. Intrinsic susceptibility pattern as for this species. Probably less pathogenic than
C. albicans and almost exclusively found in female genital tract specimens [7]
C. auris Not described Related to C. haemulonii. Fluconazole MICs higher than for C. albicans [8]
C. bracarensis Not described Closely related to C. glabrata. Susceptibility pattern as for C. glabrata (azole MICs elevated compared with
C. albicans) [9]
C. ciferrii Trichomonascus ciferrii Clinical signiﬁcance uncertain. Inherent resistance to several antifungal compounds described [10]
C. dubliniensis Not described Closely related to C. albicans. Intrinsic susceptibility pattern as for this species. However, potential for acquired
resistance to ﬂuconazole appears to be greater than for C. albicans [11]
C. fabianii Cyberlindnera fabianii Clinical signiﬁcance uncertain. Fluconazole MICs higher than for C. albicans [12]
C. famata Debaromyces hansenii This species has been reported as an infrequent cause of fungaemia. However, recent data questions if this species
is actually human pathogenic (lack of growth at 37°C and no cases conﬁrmed by sequencing [13]
C. guilliermondii Meyerozyma guilliermondii Closely related to C. fermentati and C. palmioleophila. High echinocandin and azole MICs [13]
C. haemulonii
(incl. C. duobushaemulonii)
Not described Emerging evidence suggests that it may be a human pathogen related to superﬁcial infections and central venous
catheter-related fungaemia, particularly in Brazil, the Caribbean and Asian regions. Elevated azole and amphotericin
MICs are reported. Related to C. auris [14]
C. hellenica Zygoascus meyerae Fungaemia and respiratory infection has been reported. Decreased susceptibility to ﬂuconazole, itraconazole,
caspofungin, susceptible to voriconazole [15]
C. inconspicua Not described Closely related to C. norvegensis. Susceptibility pattern similar to C. krusei (intrinsically resistant to ﬂuconazole) [16]
C. intermedia Not described Oropharyngeal colonizer, bloodstream infections, peritonitis. Susceptible to antifungal drugs except ﬂucytosine [13]
C. kefyr Kluyveromyces marxianus No inherent resistance to antifungals described
C. lipolytica Yarrowia lipolytica Clinical signiﬁcance uncertain. Fluconazole MICs higher than for C. albicans.
C. lusitaniae Clavispora lusitaniae Not a good target for amphotericin B even if MICs are in the susceptible range (≤1 mg/L) [17]
C. metapsilosis Not described Closely related to C. parapsilosis. Susceptibility pattern similar to this species (high echinocandin MICs) [18]
C. nivariensis Not described Closely related to C. glabrata. Susceptibility pattern as for C. glabrata (decreased susceptibility to azoles) [9]
C. norvegensis Pichia norvegensis Closely related to C. inconspicua. Susceptibility pattern similar to C. krusei (intrinsically resistant to ﬂuconazole) [16]
C. orthopsilosis Not described Closely related to C. parapsilosis. Susceptibility pattern similar to this species (high echinocandin MICs) [18]
C. palmioleophila Not described Phenotypically related to C. guilliermondii. High azole MICs (but low echinocandin MICs in contrast to those for
C. guilliermondii) [13]
C. pelliculosa Wickerhamomyces anomalus
(prev. Pichia anomala,
Hansenula anomala)
Fluconazole MICs higher than for C. albicans [19]
C. pulcherrima Pichia kudriavzevii
(prev. Metschnikowia
pulcherrima)
Clinical signiﬁcance uncertain
C. rugosa Not described Fluconazole MICs higher than for C. albicans [19]
C. subhashii Not described Clinical signiﬁcance uncertain
C. viswanathii Not described Clinical signiﬁcance uncertain
C. zeylanoides Not described Clinical signiﬁcance uncertain
TABLE 2. Strength of the EFISG and ECMM recommenda-
tion and quality of evidence
Strength of a recommendation (SoR)
Grade A ESCMID and ECMM strongly support a recommendation for use
Grade B ESCMID and ECMM moderately support a recommendation for use
Grade C ESCMID and ECMM marginally support a recommendation for use
Grade D ESCMID and ECMM support a recommendation against use
Quality of evidence (QoE)
Level I Evidence from at least one properly designed randomized, controlled
trial
Level IIa Evidence from at least one well-designed clinical trial, without
randomization; from cohort or case–controlled analytical studies
(preferably from more than one centre); from multiple time series;
or from dramatic results of uncontrolled experiments
Level III Evidence from opinions of respected authorities, based on clinical
experience, descriptive case studies, or reports of expert
committees
aAdded index: r: Meta-analysis or systematic review of randomized controlled
trials. t: Transferred evidence, that is, results from different patients’ cohorts, or
similar immune-status situation. h: Comparator group is a historical control. u:
Uncontrolled trial. a: Published abstract (presented at an international symposium
or meeting).
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 3), 76–98
78 Clinical Microbiology and Infection, Volume 20 Supplement 3, April 2014 CMI
neoformans), blood culture remains an essential investigation
for the detection of invasive infection and the general
recommendations concerning volume and sampling frequency
should be followed [32–34]. Emerging evidence has highlighted
the additional yield obtained for candidaemia when a fungal
blood culture bottle is included to speciﬁcally support the
growth of fungi and at the same time avoid suppression by
concomitant faster growing microorganisms [35–38]. It
remains to be demonstrated if this applies to the detection
of fungaemia due to the yeasts described herein. In the
following sections the general characteristics for the different
pathogens will be reviewed (in alphabetical order). Speciﬁc
characteristics concerning the epidemiology and species iden-
tiﬁcation are summarized in Tables 2 and 3. In most cases,
identiﬁcation to the species level requires the adoption of new
tools including matrix-assisted laser desorption/ionization time
of ﬂight mass spectrometry (MALDI-TOF-MS) or DNA
sequencing. In this context it is important to underline that
the performance of these techniques depends on the quality of
the databases employed. However, these approaches appear
promising for most of these species and are expected to play
an important role in the future (Table 4). Recommendations
regarding use of blood culture and surrogate markers are
summarized in Table 5. Finally, recommendations regarding
appropriate ﬁrst-line antifungal treatment options are summa-
rized in Table 6.
Cryptococcus
Introduction
Cryptococcus is an anamorphic basidiomycetous yeast genus that
comprises 70 species [39] but only two species C. gattii and
C. neoformans are regularly causing infections. The diagnosis and
management of these have been described in detail elsewhere
and are not included in the present guideline because they are
not uncommon or rare infections [40–43].
Other Cryptococcus species (e.g. C. albidus, C. curvatus,
C. laurentii) are prevalent worldwide and have been identiﬁed
from various environmental sources including air, soil, water,
pigeon droppings and food items such as cheese, milk, beans and
wine [39]. The species are able to grow at 37°C and have been
described as a cause of invasive human infections, with C. albidus
and C. laurentii accounting for 80% of the non-neoformans/
non-gattii cryptococcal infections [44]. Cryptococcus uniguttula-
tus, C. adeliensis and C. ﬂavescens have also been implicated in
cases of meningitis, albeit less frequently [45–48]. The clinical
presentation is similar to that for C. neoformans but the
cryptococcal antigen test is often negative and intrinsic suscep-
tibility patterns are characterized by higher MICs for several
agents [49]. Therefore, diagnosis and optimal management
depend on a high index of suspicion and a skilled mycology
laboratory service. In the literature, cultures were not always
performed and species identiﬁcations were in many cases based
solely on phenotypic methods. Therefore, reports on infections
caused by the individual species should be interpreted with
caution unless coming from reference laboratories.
Risk factors and clinical presentation
Cryptococcus adeliensis, C. albidus, C. curvatus, C. ﬂavescens,
C. laurentii and C. uniguttulatus have been recovered from
various clinical specimens [44–48,50]. The most common
underlying risk factor is impaired cellular immunity, of which
16%was related to human immunodeﬁciency virus infection in a
recent review of 44 previously published cases [44]. In addition,
C. laurentii has been linked to the presence of invasive devices
[44]. Clinical presentation involves bloodstream infection in
33–55% of the cases, neurological manifestations in 20–33%
TABLE 3. Summary of rare yeast isolates collected during the national surveillance programme in Denmark 2004–2011 and the
surveillance programme in Paris hospitals, France October 2002–May 2012. Only unique isolates are included. For comparison
and representing other parts of the world data from a US cancer centre, the Artemis study and a Brazilian study are included
DK (national)
[26,27] Paris Hosp.a
US (cancer
centre) [28]
Artemis study
1997–2007 [29]
Sao Paulo
Brazil [30]
Fungaemia isolates (total) 3982 3668 3382 NA 1195
Rare yeasts other than Candida 44 (1.1%) 188 (5.1%) 94 (2.8%) 11,240 174 (14.5%)
Cryptococcus neoformans 13 (29.5%) 137 (72.8%) NA 3,512 (31.2%) 79 (45.4%)
Cryptococcus spp. 1 (2.3%) 1 (0.5%) NA 113 (1.0%) NA
Geotrichum spp. 2 (4.5%) 19 (10.1%) 2 (5%) NA NA
Rhodotorula spp. 4 (9.1%) 5 (2.7%) 21 (51%) 462 (4.1%) 28 (16.1%)
Saccharomyces spp.b 22 (50.0%) 14 (7.4%) 8 (20%) 1,321 (11.8%) NA
Trichosporon spp. 2 (4.5%) 11 (5.9%) 8 (20%) 1,196 (10.6%) NA
Malassezia spp. 0 1 1 (2%) NA NA
Pichia anomala 0 NA 1 (2%) 28 (0.2%) 32 (18.4%)
Saprochaete capitata 0 NA NA 109 (1.0%) NA
NA, Not available.
aYEASTS Network, National Reference Centre for Invasive Mycoses and Antifungals, Paris, France (unpublished data).
bTaxonomically also a Candida species (C. robusta).
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and pulmonary infection in 5–11% of the cases, but other body
sites may also be involved including skin, eyes, peritoneum
(secondary to peritoneal dialysis) and lymph nodes (5–10%
each). Cryptococcus laurentii was associated with no mortality in
contrast to C. albidus (28% mortality) [44].
Diagnosis
Cryptococci are budding, encapsulated, round to oval yeast
cells with a size from 3 to 8 lm in ﬂuids or tissues. The cells can
be visualized by mixing the pellet (cerebrospinal ﬂuid, pleural
ﬂuid or bronchoalveolar lavage) with India ink. The capsule
surrounding the cell will appear transparent as a halo resem-
bling an egg-white around the yolk. Tissue sections can be
stained with mucicarmine or Alcian blue to highlight the capsule
and so exclude other yeasts with similar morphology. Clinical
specimens should be incubated on Sabouraud or other
selective fungal agar at 30–35°C (for up to 4 weeks in case of
prior antifungal treatment). Lysis centrifugation or culture of
the buffy coat improves the yield of fungaemia detection [40].
Creamy mucoid colonies are obtained and the colour may
darken with age. The genus is non-fermentative and identiﬁed
by the presence of a capsule, urease production and assimila-
tion pattern using commercial kits [39]. When cultured on bird
seed agar most species do not form brown to black colonies
(and can therefore be differentiated from C. neoformans and
C. gattii). There are few exceptions such as Cryptotrichosporon
anacardii [51] and Cryptococcus podzolicus [52]. Species identi-
ﬁcation requires sequencing of internal transcribed spacer (ITS)
1 + 2 regions of rDNA and/or D1/D2 domains [39,47,48,53];
MALDI-TOF-MS is a promising tool for future identiﬁcation
of uncommon yeasts including Cryptococcus species; however,
its performance will depend on the quality of the database
(T. Boekhout, unpublished observations) [54–56].
Despite sharing several capsular antigens with C. neoformans,
cryptococcal antigen detection is not a reliable diagnostic test
for non-neoformans/non-gattii cryptococcal species with only 4/
17 bloodstream cases being positive and at low titres [44,45].
Whether the poor sensitivity is attributable to differences in
capsule structure (versus C. neoformans) or lower fungal
burden remains to be clariﬁed. False-positive results have been
reported during invasive Trichosporon infections [57,58] and in
the case of rheumatoid factor [59], Capnocytophaga canimorsus
septicaemia [60], Stomatococcus mucilaginosus bacteraemia [61],
soaps and disinfectants [62]. The amount of b-1-3-D-glucan in
the cryptococcal cell wall is much lower than in for example
Candida albicans and the b-1-3-D-glucan test has not been found
useful in the diagnosis of cryptococcal disease, as exempliﬁed
by only two of 12 patients with cryptococcosis positive at a
cut-off value of 80 pg/mL [63,64]. Therefore the test is not
recommended in this context. Finally, cross-reaction with the
TABLE 5. Summary of and recommendations regarding use of blood culture and surrogate markers
Species Surrogate markers
Strength of
recommen-dation
Quality of
evidence Comment References
All Blood culture A II Volume of blood is essential. Adults: 40–60 mL either
one venepuncture or separate immediately after each
other. Repeated if signs and symptoms of fungaemia
persist.
[32–34]
Blood culture fungal medium B IIt Several studies have documented better yield for
Candida and BACTEC and BacT/ALERT BC systems if
a mycosis medium is included. Not shown speciﬁcally
for rare yeasts.
[26,35–38]
Cryptococcus other
than C. neoformans
and C. gattii
Cryptococcus antigen C III Cerebrospinal ﬂuid and serum. Sensitivity lower than
for C. neoformans. (4/17 in one study). Negative result
does not exclude cryptococcosis.
[44,45]
Asp GM D III Cross-reaction due to galactomannan in the fungal cell
wall. However, sensitivity not examined.
[65]
b-D-glucan D II b-D-glucan is not part of the cryptococcal cell wall. [63]
Geotrichum No data on surrogate markers No recom-mendation No data
Kodamaea ohmeri No data on surrogate markers No recom-mendation No data
Malassezia Isolator 10 Lysis centrifugation or
BC bottle suppl. with palmitic acid
with prolonged incubation
(2 weeks)
B III Positive microscopy and negative culture may be
suggestive, due to the lipid dependence of most
species. Subculture: Sabouraud overlaid with sterile
olive oil, Dixon agar or other lipid-containing agar.
[107,108]
Pseudozyma No data on surrogate markers No recom-mendation No data
Rhodotorula b-D-glucan C III b-D-glucan present in culture supernatant but in lower
amount and but no clinical data.
[63]
Saccharomyces b-D-glucan C III b-D-glucan present in culture supernatant but no
clinical data.
[63,180]
Candida mannan antigen C III Single clinical case and antigen similarity [179]
Saprochaete capitata Asp GM C III Cross-reaction due to galactomannan in the fungal cell
wall. However, sensitivity not examined.
[208,209]
b-D-glucan C III b-D-glucan present in culture supernatant but no
clinical data.
[63]
Trichosporon Cryptococcus antigen
Asp GM
B
C
IIu
III
Cross-reaction with cryptococcal polysaccharide and
galactomannan Ags. Dual positivity may be suggestive
for Trichosporon infection. However, sensitivity not
examined.
[57,58,246–249]
b-D-glucan D II Low sensitivity [238,250,251]
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TABLE 6. Targeted antifungal treatment of emerging invasive yeast infections. Note: intention is to cure manifest infection
Population/
manifestation Antifungal
Strength of
recommendation –
quality of evidence Comments References
Cryptococcus
other than
C. neoformans
and C. gattii
CNS and severe
inf. Induction
Amphotericina
(ﬂucytosineb)
B-III MICs of 5-FC, ﬂuconazole and other azoles often
elevated and particularly so for C. albidus,
C. laurentii and C. uniguttulatum [29,30,33,54–59]
[44–46,49,69–74]
CNS and severe inf.
Consolidation
Fluconazole ≥400
mg/day
C-III If in vitro susceptible
Non-CNS, not
severe inf.
Fluconazole ≥400
mg/day
C-III MICs of 5-FC, ﬂuconazole and other azoles often elevated
and particularly so for C. albidus, C. laurentii and
C. uniguttulatum [29,30,33,54–59]
Non-CNS, not
severe inf.
Amphotericina B-III May be preferable to ﬂuconazole for the less
azole-susceptible species
Any Echinocandins D-II Intrinsically resistant
Geotrichum
candidum
Any Amphotericina
(ﬂucytosineb)
B-III Preferred agent is amphotericin B (w/wo 5-FC). [77–80]
Any Fluconazole D-III No human data and high MIC values [77,82]
Any Voriconazole NR Low MIC values. One breakthrough failure case (while
on micafungin), but voriconazole TDM levels not
reported.
[77,78,81]
Any Echinocandins D-II In vitro resistant [77]
Kodamaea
ohmeri
Any Amphotericina B-III Most (but limited) clinical experience w
amphotericin B;
[83,85,86,92,95,96]
Any Fluconazole C-III Elevated MICs for some isolates. Fluconazole
successful in 5/6 paediatric cases, in 1/1 adult
immunocompromised patient case (ﬂuconazole
followed by itraconazole) unsuccessful in one adult
case of cellulitis [70,74,78].
[84,88,92]
Any Echinocandins C-III Two case reports showed successful outcome for one
patient each on micafungin and caspofungin
respectively (MICs higher than for C. albicans)
[91,93]
Any Voriconazole NR No data
Malassezia Severe cases Amphotericina B-III [97,106]
Non-severe cases Fluconazole B-III M. pachydermatis may be less susceptible in vitro [97,106]
Any Voriconazole C-III In vitro activity, no clinical data, exposure issues
particularly in the paediatric population
[97,106]
Any Echinocandins D-III No reference susceptibility test for Malassezia;
modiﬁed susceptibility tests suggest intrinsic
resistance
[97,106]
Any Flucytosineb D-III No reference susceptibility test for Malassezia;
modiﬁed susceptibility tests suggest intrinsic
resistance
Pseudozyma
spp.
Any, fungaemia Amphotericina A-IIu Low MICs of amphotericin B, case stories reporting
success.
[121–124]
Any, fungaemia Fluconazole D-II 5/6 clinical isolates had high MICs of ﬂuconazole [121–124]
Any, fungaemia Echinocandins D-II In vitro resistant [123,124]
Any, fungaemia Flucytosineb D-II In vitro resistant (MIC >64 mg/L) [121,123]
Any, fungaemia Voriconazole C-III In vitro activity, no clinical data, exposure issues [123,124]
Rhodotorula Any Amphotericina
(ﬂucytosineb)
A-II In vitro susceptible only to these two agents. Good
response in the case reports available.
[131,153,154]
Any Azoles D-IIu Breakthrough cases on ﬂuconazole and echinocandins.
In vitro resistant to all azoles and echinocandins
[131,147,148,153,154]
Any Echinocandins D-II Breakthrough cases on azoles and echinocandins.
In vitro resistant
[147,153,154]
Saccharomyces Any Amphotericina B-III Most clinical experience; toxicity risk higher than for
echinocandins
[178,182,183]
Any Echinocandins C-III Two successful cases in the literature
( neutropenic), no emergence of S. cerevisiae after
intro of echinocandins as ﬁrst line agents for
candidaemia, two recent failure cases neutropenic
(Arendrup MC unpublished data)
[27,182,183]
Any Amphotericin
Ba + Flucytosineb
B-III Excellent in vitro susceptibility. May be used in severe
cases or when penetration into an infected focus is
challenging.
[70,170,181,184,185]
Any Fluconazole D-III Increased occurrence in patients exposed to
ﬂuconazole; high ﬂuconazole MICs (similar to those
for C. glabrata
[26,178]
Any Discontinuation of
probiotics
A-III Probiotic containing S. boulardii has been documented
to be the origin of systemic infections.
[175,176]
Saprochaete
capitata
Any Amphotericina
(ﬂucytosineb)
B-III Most (but limited) experience. In vitro susceptibility of
amphotericin B in the intermediate range, failures in
hepatosplenic infections reported on amphotericin B
monotherapy.
[186,194,196]
Any Voriconazole B-III Less data available, but promising in vitro susceptibility [186]
Any Echinocandins D-II In vitro resistant and a case report document
breakthrough infections on an echinocandin.
[211,212]
Any Fluconazole NR In vitro resistant – but animal model data suggest
activity
[211–213]
Any CSF or interferon-c
in combination
w antifungal
treatment
C-III Improved in vitro phagocytic activity has been
observed
[194,195,206]
Sporobolomyces Any Amphotericina C-III Possibly a treatment option but insufﬁcient clinical
data
[69,222,223,230]
Any Voriconazole C-III Possibly a treatment option but insufﬁcient clinical
data
[69,225,230]
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Aspergillus galactomannan antigen test (Platelia Aspergillus;
BioRad, Marnes la Coquette, France) has been observed due
to the presence of galactoxylomannan in the cryptococcal
capsule [65]. A commercially available cryptococcal lateral ﬂow
antigen detection device (IMMY; Immuno-Mycologics, Inc.,
Norman, OK, USA), has recently been introduced as a
point-of-care test for the early diagnosis of cryptococcosis.
The test has proven effective both for serum, cerebrospinal
ﬂuid and urine samples in comparison with conventional
techniques of antigen detection but the performance for the
detection of infections due to cryptococci other than C. neo-
formans has not been evaluated [66–68].
Susceptibility testing and treatment
Cryptococci are intrinsically resistant to echinocandins. The
optimal treatment for invasive infections due to other
Cryptococcus species has not been established. Amphotericin
B alone or in combination with ﬂucytosine and ﬂuconazole
either alone or after induction therapy with amphotericin B
has been used. Predictors for mortality were infection with
C. albidus (rather than C. laurentii), age above 45 years and
central nervous system involvement [44]. In vitro susceptibility
testing suggests that C. albidus, C. curvatus and C. laurentii are
susceptible to amphotericin B with MICs comparable to those
for C. neoformans [49]. On the contrary, MICs of ﬂucytosine,
ﬂuconazole and other azoles are in most studies elevated and
particularly so for C. albidus, C. laurentii and C. uniguttulatus,
suggesting that these organisms may be less susceptible
[45,46,49,69–74]. Moreover, ﬂuconazole resistance has been
reported more frequently in patients with previous azole
exposure (83% versus 50%) [44]. The clinical implication of
these observations remains to be understood. However, initial
induction therapy with amphotericin B until clear clinical
improvement and careful evaluation of ﬂuconazole susceptibility
if step-down to this agent is considered appears to be a sound
and safe strategy.
Geotrichum candidum
Geotrichum candidum (Galactomyces candidus) is a ﬁlamentous
ascomycetous yeast that forms arthroconidia and that has rarely
been reported to be responsible for disseminated infections in
the haemato-oncology setting [75–77]. It is closely related to
Saprochaete capitata (Magnusiomyces capitatus) and Saprochaete
clavata (see below). A recent literature review of 12 invasive
cases reported since 1971 revealed that 8/12 patients had
underlying malignancy [77]. It has been anecdotally reported as a
cause of invasive skin infection [78]. The preferred agent for
invasive infections is amphotericin B with or without concom-
itant ﬂucytosine as most experience exists with this agent
[77,79,80]. Voriconazole may be a promising agent, as suggested
by good in vitro susceptibility, but only a single case is reported in
the literature with an unsuccessful outcome of a breakthrough
infection (while on micafungin) [77,78,81]. Neither echinocan-
dins nor ﬂuconazole can be recommended because of highMICs
and no clinical support for efﬁcacy [77,82].
Kodamaea ohmeri
Introduction
Kodamaea (Pichia) ohmeri is a rarely occurring yeast that has
recently been identiﬁed as a cause of fungaemia, endocarditis,
cellulitis, funguria and peritonitis in neonates and children [83–
87], and in both immunocompromised [88–91] and immuno-
competent [92,93] adult patients. The anamorphic state is
Candida guilliermondii var. membranaefaciens, and has been
confused with Candida guilliermondii (for which the teleomorphic
state is Meyerozyma guilliermondii). Recent literature invariably
does not acknowledge the anamorphic state (and readers may
therefore not recognize this species as a Candida sp.), sowe have
included K. ohmeri in this guideline. Kodamaea ohmeri may be
Table 6 (Continued)
Population/
manifestation Antifungal
Strength of
recommendation –
quality of evidence Comments References
Any Echinocandins D-II In vitro resistant [69,230]
Any Fluconazole D-II In vitro resistant [69,230]
Trichosporon Any Voriconazole B-III Preferred therapy, but as data are scarce [233,237,238,259,260]
Any Fluconazole C-III Some clinical evidence for usefulness,
but also some isolates with higher MICs
[192,232,238]
Any Echinocandins D-II In vitro resistant [237–239,256,262]
Any Amphotericina D-III Low success rates on amphotericin
B and in vitro resistance reported
[192,232,261,265–267,270]
Any Flucytosineb D-III In vitro resistant
5-FC, ﬂucytosine; CNS, central nervous system; inf., infection; TDM, therapeutic drug monitoring; w/wo, with/without.
aAmphotericin, wherever mentioned, includes amphotericin B deoxycholate and its lipid formulations. Lipid formulations are preferred due to lower toxicity and liposomal
amphotericin B speciﬁcally whenever central nervous system penetration is warranted.
bFlucytosine, wherever mentioned, is a possible option particularly in cases where penetration issues (e.g. central nervous system infection) or severity, suggest combination
therapy may improve outcome. Flucytosine should only be used in combination due to the risk of selection of resistance and therapeutic drug monitoring is highly recommended
due to the narrow therapeutic index.
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misidentiﬁed as Candida tropicalis [84], Candida haemulonii or
Candida parapsilosis [94] by traditional methods and molecular
identiﬁcation is mandatory.
Risk factors/clinical presentation
There are <30 cases described in the world literature, which
are mainly sporadic reports but also include two Asian series
with several cases [84,94]. In one of these, the hands of a
healthcare worker at a surgical ward were colonized with
K. ohmeri, suggesting a nosocomial outbreak [84].
Diagnosis
Blood culture remains the cornerstone in the diagnosis of
invasive infection. On solid media, K. ohmeri forms Candida-like
colonies, which on CHROMagar (BioMerieux, Marcy l’Etoile,
France) change colour from pink to blue within 48 h [88].
Although mis-classiﬁcation as Candida tropicalis has been
reported, correct species identiﬁcation can be obtained by
biochemical tests such as the Vitek 2 and API ID32C or
sequencing of the rDNA loci [84,88].
Susceptibility testing and treatment
Susceptibility testing suggests that the susceptibility pattern
mirrors that for Candida glabrata with azole MICs higher than
those for Candida albicans (ﬂuconazole: 2–64 mg/L; voriconaz-
ole: 0.03–8 mg/L, posaconazole 0.06–4 mg/L, respectively), but
amphotericin B and echinocandin MICs in the range that would
be interpreted as susceptible for Candida albicans (amphotericin
B: 0.25–1 mg/L, caspofungin: 0.125–1 mg/L, micafungin: 0.03–
0.06 mg/L, respectively) [84,94]. Most cases have been treated
with liposomal amphotericin B (or amphotericin B deoxycho-
late) and with good response [83,85,86,92,95,96]. Fluconazole
was successful in 5/6 paediatric cases, in 1/1 adult immunocom-
promised patient (ﬂuconazole followed by itraconazole) and
was associated with failure in one adult case of cellulitis
[84,88,92]. Finally, caspofungin or micafungin treatment has
been successful in one case each [91,93]. Hence, although there
are insufﬁcient data to support a ﬁrm treatment recommenda-
tion, amphotericin B appears to be an attractive ﬁrst-line agent
and echinocandins are possibly promising alternative candidates.
Susceptibility testing is recommended not only to guide
treatment but also to provide MIC–outcome relationships and
hence data for future optimized treatment recommendations.
Malassezia
Introduction
Malassezia species are basidiomycetous yeasts and part of our
normal skin microbiota. The genus includes 14 species of
which 13 are lipid dependent. These include M. furfur,
M. sympodialis, M. globosa, M. obtusa, M. restricta, M. sloofﬁae,
M. dermatitis, M. japonica, M. nana, M. yamatoensis, M. equina,
M. caprae and M. cuniculi. Malassezia pachydermatis, however,
is able to grow on routine media without the addition of oil or
other sources of lipid. Malassezia sympodialis, M. globosa,
M. sloofﬁae and M. restricta are the most frequently found
species responsible for colonization of humans.
Risk factors/clinical presentation
Malassezia species may cause various skin manifestations
including pityriasis versicolor, seborrhoeic dermatitis, dandruff,
atopic eczema and folliculitis and less commonly onychomy-
cosis [97]. These skin manifestations are common and are
typically diagnosed and managed in the primary healthcare
sector or by dermatologists [97]. For their management, we
would refer the reader to local and international guidelines.
However, skin colonization and infection may be a source for
transmission to vulnerable patient groups susceptible to
invasive infections [97]. Both the non-lipid-dependent species
M. pachydermatis and the lipid-dependent Malassezia spp.
(almost all reported as caused by M. furfur) have been
reported to cause systemic infections [97–99]. As an example,
M. pachydermatis, which is known to cause external otitis in
dogs, has been isolated from the hands of dog owners,
including healthcare providers such as nurses, and associated
with clusters of infections in neonates [98,100–102]. Apart
from contact with a potential carrier, other risk factors for
M. pachydermatis include increased median neonatal acute
physiology score and more than 9 days of arterial catheter-
ization [98]. Notably, M. pachydermatis can persist for a long
time on surfaces of incubators, which may serve as a source of
infection for neonates [103].
Systemic infections due to lipid-dependent Malassezia
species mainly occur in the following host groups: (i) infants
on lipid-containing parenteral nutrition and (ii) children and
adults with various forms of immunosuppression and under-
lying diseases [97,104]. Risk factors for fungaemia related to
non-lipid total parenteral nutrition are the following: chronic
ambulatory peritoneal dialysis (due to lipids leaking from the
gastrointestinal tract), haematological malignancy, cancer and
Crohn’s disease and most cases arise in patients with a CVC
[97,105,106].
Diagnosis
The diagnosis of invasive Malassezia infections is challenging
because of the lipid-dependent nature of most species. Hence,
special media, such as modiﬁed Dixon or modiﬁed Leeming
and Notham agar, or the use of Sabouraud agar with the
addition of a few drops of sterile olive oil is required. The
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performance of the various modern automated blood culture
systems for the detection of Malassezia species has not been
systematically studied, however, the use of the Isolator 10
system (with subculture of lipid-containing agar) or supple-
mentation of the blood culture ﬂask with palmitic acid has
been shown to be required for the detection of lipid-depen-
dent species in earlier blood culture systems [107,108].
Inoculated blood culture media should be incubated for up
to 2 weeks. Colonies on solid agar are cream to beige. Yeast
cells are round or oval with thick walls with a size varying from
2 to 8 m. Cell division is via monopolar budding with buds that
may be nearly as broad as the mother cell in many cases,
leading to a ﬂask-like appearance of the cells.
Malassezia species may be distinguished phenotypically using
morphology and a series of biochemical tests as well as using
molecular tools [109–111] and by MALDI-TOF-MS (T.
Boekhout, unpublished observation). Full protocols for phe-
notypic identiﬁcation are provided by Gueho-Kellermann et al.
[112]. For clinical management at the level of the individual
patient, species identiﬁcation is less important, although it is
obviously needed for epidemiological surveillance and out-
break investigation.
Susceptibility testing and treatment
Susceptibility testing of Malassezia has not been standardized
because growth is not supported on the standard RPMI
growth medium recommended for yeast and mould testing
by CLSI and EUCAST. Signiﬁcant variation and broad range
MICs have been reported in various publications depending
on the medium used, which may result in random/erroneous
susceptibility classiﬁcation [113]. Some reports suggest that
in vitro ﬂuconazole resistance may be encountered more
often in M. pachydermatis [114,115]. The clinical implication
of this ﬁnding remains unclear. So far susceptibility testing
for guiding treatment cannot be recommended. As for the
other rare invasive yeast infections, larger patient series are
lacking, and hence evidence-based treatment recommenda-
tions cannot be made. The key factors in the management of
invasive Malassezia infection are removal of the CVC,
discontinuation of the parenteral lipid and institution of
systemic antifungal treatment. Most experience is with
ﬂuconazole and amphotericin B, which are the preferred
agents [106,116,117]. In general MICs are lower for voric-
onazole than for ﬂuconazole for most species, however, so
is the voriconazole exposure, particularly in the paediatric
population, which is a reason to strongly consider thera-
peutic drug monitoring if voriconazole is prescribed [118–
120]. Additionally, voriconazole is associated with more
side-effects and drug–drug interactions and is not licensed
for neonates or children <2 years old. Future studies are
warranted to elucidate which antifungal treatment is optimal.
In vitro resistance to ﬂucytosine and echinocandins appears
to be a consistent ﬁnding and therefore these drug classes
are not recommended [101,116].
Pseudozyma
Introduction
Pseudozyma species are basidiomycetous plant pathogens,
which belong to the Ustilaginales. The genus today contains
at least 20 species and was not recognized as a human
pathogen until 2003 when three Pseudozyma species—Pseud-
ozyma antarctica, Pseudozyma parantarctica and Pseudozyma
thailandica—were isolated from the blood of three Thai
patients [121]. Fungaemia due to Pseudozyma aphidis was
subsequently reported from the USA in 2008 [122] and
recently in a neonate from India [123].
Risk factors/clinical presentation
So far infections due to Pseudozyma have been reported from
Asia (Korea, China, India, Thailand), Brazil and the USA [123].
Risk factors associated with invasive Pseudozyma infections are
similar to those of non-albicans Candida spp., i.e. extremes of
age, cancer chemotherapy, neutropenia (<3000 cells/lL),
presence of a CVC and severe thrombocytopenia [121–124].
Invasive Pseudozyma spp. infection most often presents with
fungaemia. Moreover, deep-seated focal infections including
brain abscess [125] and pleural cavity have been reported
[124]. Finally, a single case of a mycetoma due to co-infection
with Nocardia after traumatic inoculation in an Asian farmer
has been described [126].
Diagnosis
The main stay in the diagnosis of invasive Pseudozyma spp.
infection is blood culturing and when, focal infection is
suspected, culture of relevant tissue samples. On Sabouraud
agar Pseudozyma species form rapidly expanding moist,
tan-yellow and wrinkled yeast colonies [122,124] and on
CHROMagar Candida medium P. aphidis forms rough green
colonies after 48–72 h of incubation at 37°C (no data for the
other species). Microscopic examination shows fusiform
spindle-shaped elongated blastoconidia and the presence of
hyphae. Germ tube test and chlamydoconidia formation are
negative. Isolates show positive test for diazonium blue B and
hydrolyse urea. Growth is inhibited on 0.1% cyclohexi-
mide-containing medium. API ID 32C and VITEK2 compact
generally give non-conclusive proﬁle(s). Ampliﬁcation and
sequencing of the ITS and/or D1/D2 domain is necessary for
a proper identiﬁcation [121–123,125,126].
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Susceptibility testing and treatment
Low MIC values of amphotericin B, posaconazole (0.03 mg/L),
voriconazole (0.06 mg/L) and isavuconazole (0.25 mg/L) have
been reported. Susceptibility of itraconazole was variable and
5/6 isolates had MICs of ﬂuconazole in the range of 4 to
greater than 64 mg/L. The echinocandins (>4 mg/L) and
ﬂucytosine (>64 mg/L) are not active against Pseudozyma
[123]. Although the available data are too limited to provide
ﬁrm treatment recommendations, ﬁrst-line options may be
amphotericin B or voriconazole whereas echinocandins,
ﬂuconazole and ﬂucytosine should be avoided.
Rhodotorula
Introduction
Clinically relevant red yeasts belong to two genera: Rhodotorula
and Sporobolomyces (see below). Rhodotorula species are com-
mon environmental basidiomycetous yeasts, which can be found
in soil, ocean and lake water, fruit juice and milk, and on shower
curtains and toothbrushes [30,127]. Today, the genus contains
46 species [128] of which three have been described as rare
human pathogens: R. mucilaginosa (also known as R. rubra),
R. glutinis and R. minuta [30,129,130]. The association of
R. mucilaginosa with humans is well documented and this yeast
has been isolated from skin, sputum and digestive tract samples
including faeces, forming part of the normal human microbiota.
This species accounts for themajority of the infections (74–79%)
followed by R. glutinis (7.7%) [130,131]. In a signiﬁcant propor-
tion of the reported cases the species identiﬁcation is not
available (17%); furthermore, species identiﬁcation is not reliable
by methods normally available in the routine microbiology
laboratory, and identiﬁcation using sequence analysis of the
D1D2 domains of the large subunit ribosomal DNA (rDNA)
and the ITS 1 + 2 regions of the rDNA is needed [30,130].
Risk factors/clinical presentation
Opportunistic fungal infections due to Rhodotorula have
emerged after the ﬁrst case was reported in 1985, and the
most common predisposing factor appears to be the presence
of a CVC and underlying haematological disease [28,127,130–
135]. However, Rhodotorula fungaemia, peritonitis, endocardi-
tis or meningitis have also been reported in other vulnerable
patient groups, including patients with AIDS, extensive burns,
continuous ambulatory peritoneal dialysis, cirrhosis, those who
have undergone intra-abdominal surgery, intravenous drug
abusers and critically ill ICU patients [130,136–146]. Notably, a
signiﬁcant number of cases are breakthrough infections during
ﬂuconazole or echinocandin treatment [131,134,135,147,148].
Infections appear to be less common in Nordic countries
compared with the warmer regions [26,28,149]. Moreover,
Rhodotorula has also been found on the hands of healthcare
workers in Egypt [150], and it has a high afﬁnity to adhere to
plastic surfaces and can form bioﬁlms [28,151]. Hence, medical
equipment including ﬂexible endoscopes, various utensils and
furniture in the patient’s room can easily become colonized.
These observations suggest geographical differences in the
epidemiology and possibly a potential role of differences in
hygiene procedures [30,148,150].
Diagnosis
The mainstay in the diagnosis of invasive Rhodotorula spp.
infection is blood culture as 79% of the systemic infections
presents as fungaemia [130]. Of note, isolates of Rhodotorula
have been found to cross react with the Candida glabrata/
Candida krusei probe in the commercially available ﬂuorescence
in situ hybridization test for presumptive species identiﬁcation
of positive blood cultures, which might lead to inappropriate
echinocandin treatment [152]. A CVC is often involved and
therefore the catheter tip should be cultured when the CVC is
removed to capture cases where blood cultures are falsely
negative [127]. Rhodotorula isolates are easily recognizable in
the laboratory by their distinctive orange to salmon-coloured
mucoid colonies. Cells of Rhodotorula spp. are subglobose, oval
to elongate, with or without small capsules, may sometimes
form rudimentary hyphae but not ballistoconidia, produce
urease but fail to ferment carbohydrates.
Antigen detection has not been reported in clinical cases of
systemic Rhodotorula infections. b-1-3-D-glucan has been
detected in the supernatant from three isolates of R. mucilag-
inosa (syn. R. rubra) at an average concentration of two-thirds
of that of Candida spp. [63]. Whether the b-1-3-D-glucan test
would be useful as a surrogate marker for invasive Rhodotorula
infection remains to be investigated.
Susceptibility testing and treatment
Susceptibility testing has yielded amphotericin B MICs of
<1 mg/L and ﬂucytosine MICs of <0.5 mg/L, but ﬂuconazole
MICs of >32 mg/L and voriconazole, itraconazole and posa-
conazole median MICs of 2 mg/L, which is above the
breakpoints for not only Candida albicans but also Aspergillus
fumigatus [153–157]. Hence, Rhodotorula species are regarded
as intrinsically resistant to azoles and echinocandins, but
susceptible to amphotericin B and ﬂucytosine [153,158,159].
This is further supported by the ﬁnding that many cases have
been breakthrough infections during ﬂuconazole or echino-
candin treatment [131,147,148]. Consequently, the preferred
treatment of choice is with any kind of amphotericin B
preparation. With such treatment, an overall mortality was
reported as 13.8% in the haematological setting and ranges
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from 0% in patients with non-Hodgkin’s lymphoma to 21% in
patients with acute leukaemia [30,127,131,160]. If present,
withdrawal of CVC is strongly recommended [130–
133,135,147] and sometimes reported to be efﬁcacious
without any accompanying antifungal treatment [28,161].
Furthermore, cases of chronic ambulatory peritoneal dialy-
sis-associated Rhodotorula peritonitis have been diagnosed and
successfully treated (5/6 patients cured) with catheter removal
(5/6 patients) and systemic or intraperitoneal antifungal
therapy (amphotericin B in 5/6 patients or ketoconazole 1/6
patients, which is today regarded as an obsolete compound for
oral administration, in one case) [130,138,162,163]. There are
anecdotal reports indicating improvement of fungal infection
under ﬂuconazole and miconazole treatment despite in vitro
resistance and in patients without antifungal treatment
[130,164]. However, since there are no conﬁrmatory trials
for treatment of Rhodotorula infections, such practice should be
avoided, especially in seriously ill patients.
Saccharomyces
Introduction
Saccharomyces cerevisiae, also known as baker’s or brewer’s
yeast, is a low pathogenic ascomycetous yeast. Saccharomyces
boulardii, a genetically similar subtype [165,166], is used as a
probiotic for prevention and treatment of various sorts of
diarrhoea and recurrent Clostridium difﬁcile-associated diarrhoea
[167–169] and shouldbeavoided in immunocompromisedhosts.
The anamorphic state of S. cerevisiae is sometimes referred to as
Candida robusta. As the species is closely related to Candida
glabrata phylogenetically it is not surprising that the clinical and
microbiological characteristics are similar to this species.
Risk factors/clinical presentation
Saccharomyces cerevisiae may be found as a harmless and
transient digestive commensal and colonizer of mucosal
surfaces of normal individuals. It can, however, also be
involved in mucosal infections like vaginitis, particularly in
ﬂuconazole-exposed women with recurrent vulvo-vaginal
candidiasis, and in bloodstream infections, again particularly
in ﬂuconazole-exposed patients [35,170]. Cases of fungaemia
and disseminated infection have been described in vulnerable
patients after treatment with the S. boulardii probiotic com-
pound [171–176], and also as nosocomial infection in a patient
that shared a room with a patient receiving probiotic,
suggesting transfer via contaminated hands of the nursing staff
[177]. In a recent review of 92 cases of invasive Saccharomyces
infections, S. boulardii accounted for half of these, was less
often associated with an underlying immunocompromised
condition and more often associated with a favourable
outcome [178]. Use of probiotics in debilitated patients, in
ICU, in neutropenic patients, in preterm newborns or in
patients with central lines should be carefully considered.
Diagnosis
Invasive infection is most often diagnosed by microscopy and
culture. Yeast cells are round to oval and larger than Candida
glabrata cells. Ascospores are occasionally seen and short
pseudohyphaemay be formed but are not typical; urease activity
is absent. Candida mannan antigen positivity has been anecdot-
ally reported in patients with fungaemia but it remains unclear if
this test can be used for diagnosis [179]. Similarly, b-1-3-D-glu-
can has been found in culture supernatant from S. cerevisiae at
quantities of approximately 85% compared with that from
Candida cultures and this test has been reported positive in case
reports of Saccharomyces bloodstream infection and on culture
supernatants from S. cerevisiae cultures, but the diagnostic
performance has not been systematically studied [63,180].
Susceptibility testing and treatment
The in vitro susceptibility pattern is similar to that of Candida
glabrata, with elevated azole MICs, but echinocandin MICs only
a few dilutions higher than for Candida albicans and low
amphotericin B and ﬂucytosine MICs [70,170,181]. Most clinical
experience exists with ﬂuconazole and amphotericin B, for
which favourable outcome was observed for 60% and 77.7%,
respectively [178]. The clinical experience with the echinocan-
din class of drugs is limited. Two cases have been reported in
the literature and were successfully treated [182,183]. How-
ever, two recent failures, one of which with autopsy docu-
mented multi-organ dissemination, have also been observed
(M. C. Arendrup, unpublished observations). Finally, ampho-
tericin B with or without ﬂucytosine has been used in severe or
recurrent cases [184,185] but the role of this combination
remains to be established. In addition to the systemic antifungal
therapy, it is strongly recommended that probiotics containing
S. boulardii are discontinued and indwelling foreign bodies are
removed, when possible, because this organism, like many
other yeasts, is capable of forming bioﬁlms [176].
Saprochaete
Introduction
Saprochaete capitata (Teleomorph: Magnusiomyces capitatus,
previously named Geotrichum capitatum, Trichosporon capitatum
or Blastoschizomyces capitatus) is a non-fermentative,
non-encapsulated, urease-negative ascomycetous yeast. It is
found in environmental sources such as wood and soil, in
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animals (including bovine mastitis and poultry faeces) and has
been found in dishwashers [133,186–188]. In addition, S. cap-
itata is part of the normal microbiota of human skin and is
frequently isolated from sputum and the digestive tract of
healthy people [186].
Risk factors/clinical presentation
Saprochaete capitata is a rare, but emerging yeast mostly
responsible for often lethal fungaemia in patients with
profound neutropenia in the haematology setting [186,189–
191]. This patient category represents up to 92% of reported
cases and 75% of them have been reported from Italy, Spain
and France [192]. Mortality associated with disseminated
infections has been estimated to be 57% in the haematology
population [192,193]. Of note, Geotrichum spp. represented 5%
(2/41) of non-Candida, non-Cryptococcus fungaemia cases
among haematological patients in a tertiary cancer centre in
Houston, suggesting that this species is still a rare invasive
pathogen [28]. In the haemato-oncology setting, 60–80% of
patients present with deep organ involvement [193]. Indeed, it
has been recognized as a cause of skin lesions similar to those
observed during disseminated candidiasis, hepatosplenic
abscesses [194,195], pancreatic infections [196], brain
abscesses [195], funguria [197], acute renal failure due to
fungal occlusion of glomeruli [198] and osteomyelitis, mostly
with vertebral involvement [199–201]. Central venous cathe-
ters have been recognized as a potential portal of entry [193].
A common hospital source has been advocated for several
clusters [186,202] and more recently, it has been conﬁrmed by
sequencing that S. capitata in milk vacuum ﬂasks was the origin
of an outbreak in four patients in Barcelona [203]. No
subsequent cases occurred when the identiﬁed contaminated
source was withdrawn [203].
Outside the oncology context, S. capitata has been respon-
sible for prosthetic valve endocarditis [204], pneumonia [205],
fungaemia due to contaminated intravenous ﬂuid [206] and
meningitis [207].
Diagnosis
Most cases of S. capitata fungaemia have been diagnosed by
means of blood culture. On solid media, S. capitata colonies are
white to cream and isolates produce true hyphae, pseudohyp-
hae, blastoconidia, arthroconidia and annelloconidia. In vitro and
in vivo studies have revealed that Magnusiomyces capitatus
antigens may cross-react with the Aspergillus galactomannan
assay [208,209]. b-1-3-D-glucan can be detected in vitro in culture
supernatant at amounts of 88% compared with that for Candida
spp. [63], but there is no experience of glucan detection during
invasive human cases. The species can also be identiﬁed by
MALDI-TOF-MS (T. Boekhout, unpublished observation).
Susceptibility testing and treatment
In vitro susceptibility data suggest that S. capitata is susceptible
to ﬂucytosine (MIC values 0.25–0.5 mg/L), itraconazole,
voriconazole and posaconazole (MIC ranges: 0.12–0.50,
0.25–0.5 and 0.03–0.25 mg/L, respectively), but not to
ﬂuconazole (MIC between 16 and 32 mg/L) [193,202,210].
The MICs for amphotericin B ranged between 0.5 and 2.0
[186]. Saprochaete capitata can be considered intrinsically
resistant to echinocandins and S. capitata was the cause of at
least ﬁve reported episodes of breakthrough infection in
neutropenic patients receiving echinocandins [211,212].
Finally, various combination regimens were not superior to
high-dose ﬂuconazole in an experimental animal model of
Blastoschizomyces capitatus infection (MICs of 8 and 16 mg/L)
[213]. The clinical implication of the conﬂicting observations
regarding in vitro and in vivo activity of ﬂuconazole remains to
be understood.
There are not enough clinical data to assess the optimal
treatment for S. capitata in haematology patients. However,
based on in vitro data and the limited clinical data available, any
amphotericin B formulation with or without ﬂucytosine can be
recommended [186,196]. Failure despite high-dose liposomal
amphotericin B (7 mg/kg) has been reported in the context of
hepatosplenic infection and neutropenic sepsis [191,194].
Voriconazole exhibits a promising activity in vitro [186] and
some authors have suggested the use of voriconazole and
amphotericin B combination therapy [193,214]. Of note, in the
above-mentioned animal model, high-dose ﬂuconazole was
more efﬁcacious than amphotericin B, ﬂucytosine or vorico-
nazole monotherapy [213]. Although echinocandin MIC values
are elevated, isolated case reports have suggested the
potential interest of the combination of caspofungin and
voriconazole [215,216]. The role of echinocandins as part of
combination therapy for S. capitata infections remains to be
clariﬁed.
Early removal of the catheter is an important complemen-
tary treatment as it has been the likely source of the infection
in some cases [186,189] and as removal was shown as a
prognostic indicator for success in one study [193]. Other
adjuvant therapies to improve the phagocytic activity such as
colony-stimulating factors, granulocyte transfusions and inter-
feron-c have been combined with antifungal drugs with some
success [194,195,217].
Saprochaete clavata (Geotrichum clavatum), which is closely
related to S. capitata, has only very infrequently been
described as involved in invasive human infection. However,
33 cases of S. clavata invasive infections were recently
reported in France from January 2009 to August 2012, of
which 17 cases were diagnosed within 2 months as part of an
outbreak in haematology wards in 2012 (Vaux, ECCMID 2013,
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O 505). It remains to be determined if the low number of
reported cases is the result of difﬁcult species identiﬁcation
and confusion with related species or if it is indeed a very
uncommon infection outside isolated outbreaks.
Sporobolomyces
Introduction
Sporobolomyces species are usually red-to-orange pigmented
basidiomycetous yeasts, that, next to regular budding cells,
form ballistoconidia. Phylogenetically, they are closely related
to Rhodotorula species. The 53 species occur widely in nature,
especially on leaf surfaces, but also in soil, fruits etc. and
Sporobolomyces is detected in indoor air, particularly in the
summer season [218–221].
Risk factors/clinical presentation
Sporobolomyces have been reported as the cause of sporadic
invasive bloodstream infections particularly in AIDS patients
[222,223]. A single case of meningitis due to Sporobolomyces
roseus has been described in an immunocompetent cocaine
abuser presenting with a 1-week history of severe headache
and neck stiffness but no cerebrospinal ﬂuid pleocytosis [224].
The cerebrospinal ﬂuid was culture negative but the yeast was
detected by molecular assays in two separate cerebrospinal
ﬂuid specimens. Amphotericin B has been efﬁcacious in
fungaemic and meningitis cases [222,224]. A single case of
endogenous endophthalmitis due to Sporobolomyces salmoni-
color in a patient with a history of pelvic inﬂammatory disease
2 years earlier has been reported [225]. The patient recov-
ered following intravitreal amphotericin B (5 lg) and systemic
voriconazole 200 mg twice daily. Finally, dermatitis due to
Sporobolomyces holsaticus and allergic respiratory disease
linked to Sporobolomyces exposure have been reported
[226–228].
Diagnosis
Colonies of Sporobolomyces species are usually red or orange in
colour and are similar to those of Rhodotorula species. They
differ from the latter by the formation of ballistoconidia that
are actively discharged, which usually lead to the formation of
many small satellite colonies. The optimal growth temperature
is 25–30°C. Some isolates may fail to grow well at 35–37°C
[218]. Species identiﬁcation requires sequence analysis of the
D1/D2 domains and the ITS1 + 2 regions of the rDNA. The
performance of indirect tests such as b-1-3-D-glucan has not
been investigated. Due to the ubiquitous presence of Sporo-
bolomyces contamination, transient colonization or pseudoin-
fection should be considered [223,224,229].
Susceptibility testing and treatment
In vitro susceptibility testing has been investigated for a limited
number of Sporobolomyces salmonicolor isolates and suggests
that this species is intrinsically resistant to ﬂuconazole and
echinocandins (MIC ranges 8–256 and ≥128 mg/L of ﬂuconaz-
ole and micafungin, respectively), but susceptible to vorico-
nazole and terbinaﬁne (0.03–2 and 0.06–0.12 mg/L,
respectively) [69]. The MIC range of amphotericin B and
itraconazole was 0.5–8 and 0.03–4 mg/L, respectively, sug-
gesting variable susceptibility [69,230]. Although the available
data are too limited to provide ﬁrm treatment recommenda-
tions, ﬁrst-line options may be amphotericin B or voriconazole
whereas echinocandins and ﬂuconazole should be avoided
[69,222,223,225,230]. Susceptibility testing is recommended.
Trichosporon
Introduction
Trichosporon species are urease-positive, non-encapsulated
basidiomycetous yeasts with no known sexual state. They
are widely distributed in the environment and regularly found
on normal skin, particularly in the peri-genital areas, and
occasionally as part of the normal gastrointestinal or upper
respiratory microﬂora [133,231]. The most characteristic
morphological feature is the formation of cylinder-shaped
arthroconidia in addition to pseudohyphae, septate hyphae and
blastoconidia. The genus has undergone a major taxonomic
reclassiﬁcation and today 37 species are described that belong
to at least ﬁve phylogenetic clades [231]. However, only 16
species have been associated with human infection [231]. The
vast majority of cases is caused by Trichosporon asahii (74%),
followed by T. dermatis (12%) [232]. An obvious challenge in
this respect is that a signiﬁcant part of the existing literature
does not provide a correct or unique species identiﬁcation and
hence species-speciﬁc data are limited.
Risk factors/clinical presentation
In humans, Trichosporon has been associated with white piedra
and hypersensitivity pneumonia particularly in hot and humid
climates (16–30%). In the immunocompromised host, invasive
infections such as fungaemia, endocarditis, peritonitis and
meningitis have also been reported. Most common risk factors
for invasive infections are underlying malignant haematological
disease with long-term neutropenia [192,232,233] or with
neutrophil dysfunction such as chronic granulomatous disease
[234]. Finally, a recent report suggests that T. mycotoxinivorans
may be an emerging pulmonary pathogen in patients with cystic
ﬁbrosis [235]. Males more often contract the infection and
predisposing factors are the presence of a CVC, ICU stay,
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peritoneal dialysis, steroid use and cytotoxic chemotherapy
[192,231,232,236]. Previous other fungal systemic infection is
not uncommon and breakthrough cases in patients receiving
ﬂuconazole or echinocandin have been described [237–239].
The infection most commonly presents as fungaemia (75%), in
approximately 50% of the cases associated with metastatic skin
lesions [232,233]. Renal involvement may occur and be
associated with haematuria and funguria [232]. In immuno-
compromised patients, Trichosporon is increasingly seen at
some centres among invasive yeast infections other than
Candida and Cryptococcus and associated with a mortality rate
of up to 80% [236,240,241], though 55% has been reported in
a more recent report from Taiwan [232]. Of note, rare clinical
cases have been reported in neonates and in intravenous drug
abusers [242–244].
Diagnosis
The cornerstone in the diagnosis of invasive infection is
microscopy (for the detection of fungal disease) and culture.
On solid media, colonies are white, but on CHROMagar
T. asahii forms characteristic dirty green colonies. Trichosporon
species share antigens with Cryptococcus and Aspergillus and a
number of reports have demonstrated cross-reaction for the
cryptococcal antigen and/or galactomannan antigen kits
[57,58,245–249]. Therefore, dual positivity in these tests may
be an indicator of invasive trichosporonosis; however, the
sensitivity and speciﬁcity of this approach has not been deﬁned
[57,231,245]. On the other hand the b-1-3-D-glucan tests have
been associated with a low diagnostic sensitivity for trichosp-
oronosis [245,250,251]. Molecular tests, including direct
detection on blood or formalin-ﬁxed parafﬁn-embedded tissue
samples, are being developed but are not yet standardized
[252–255]. Reliable species identiﬁcation requires molecular
identiﬁcation with sequencing of the ITS 1 + 2 (D1/D2
domain) or even the intergenic spacer region (IGS1) of the
rDNA [256–258]. MALDI-TOF-MS appears to be a promising
identiﬁcation tool (with an extensive database) [259].
Susceptibility testing and treatment
Emerging experience suggests that azoles are the primary drug
class for the treatment of invasive trichosporonosis
[192,232,233,237,238,260,261]. Several of the species are
resistant in vitro to amphotericin B with MICs ≥2 mg/L,
including T. asahii [256,257,262,263]. Trichosporon species are
resistant to ﬂucytosine (MICs 4–128 mg/L) and to the
echinocandins (MICs >16 mg/L) [239,263,264]. In patients
with systemic trichosporonosis and underlying haematological
disease poor response rates (i.e. between 16% and 24%) on
amphotericin B have been reported and therefore this agent is
not recommended for invasive infections [192,231,265–267].
Triazoles on the other hand have been found to be superior to
other antifungal drug classes in prophylaxis and treatment
[232,238,268]. Most published experience concerns the use of
ﬂuconazole. However, variations in susceptibility in vitro may
suggest that not all species and isolates are equally susceptible
to this agent [257]. Voriconazole is the preferred agent
because it displays good in vitro activity against most Tricho-
sporon species and isolates and has been associated with good
in vivo outcome in most cases of clinical and animal studies
[232,233,256,261,263,269–271]. In addition to triazole treat-
ment, resolution of myelosuppression and removal of vascular
catheters are other confounders related with increased
survival [28,192,231,237,238].
Conclusion
Rare yeasts other than Candida and Cryptococcus neoformans/
gattii are commonly found in the environment and as skin or
mucosal colonizers in humans. Some of them may be
considered as true emergent opportunistic pathogens in
Europe, although the number of reported episodes remains
low because of their low pathogenicity even in patients with
severely compromised immunity, particularly those with
haematological malignancies and a CVC.
Several of these rare yeasts possess intrinsic or variable
resistance to antifungals including echinocandins (to which
only Saccharomyces spp. and K. ohmeri are presumably
susceptible) and even polyenes (Trichosporon spp.) or azoles
(Rhodotorula spp.; some M. capitatus isolates). This may
explain the occurrence of breakthrough infections during
empiric antifungal therapy in neutropenic patients. Ampho-
tericin B is among the recommended ﬁrst-line treatment
options for these infections except for Trichosporon. Com-
bination with ﬂucytosine may be considered particularly in
severe cases or cases where drug penetration may be
suboptimal provided the infecting organism is susceptible. In
agreement with the recommendations provided in the
Candida guideline amphotericin B lipid formulations may
be considered preferable to conventional deoxycholate
amphotericin B for toxicity reasons and liposomal ampho-
tericin B particularly for infections involving the CNS
[3,5,6,272,273].
Genus identiﬁcation is mandatory for clinical management
and should be performed and provided in a timely manner.
Species identiﬁcation of these rare yeasts, however, remains
difﬁcult and often requires reference expertise and adoption of
modern techniques including molecular analysis or MALDI--
TOF-MS (with an extensive database). Whether or not the
precise species identiﬁcation (outside cryptococcosis) may
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have an impact on the individual clinical management remains
to be documented; however, its use and value for epidemi-
ological surveillance and outbreak investigation has been
documented beyond doubt.
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